α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration

Dysregulation of dopamine homeostasis and elevation of the cytosolic level of the transmitter have been suggested to underlie the vulnerability of catecholaminergic neurons in Parkinson’s disease. Because several known mutations in α-synuclein or overexpression of the wild-type (WT) protein causes familial forms of Parkinson’s disease, we investigated possible links between α-synuclein pathogenesis and dopamine homeostasis. Chromaffin cells isolated from transgenic mice that overexpress A30P α-synuclein displayed significantly increased cytosolic catecholamine levels as measured by intracellular patch electrochemistry, whereas cells overexpressing the WT protein and those from knock-out animals were not different from controls. Likewise, catechol concentrations were higher in l-DOPA-treated PC12 cells overexpressing A30P or A53T compared with those expressing WT α-synuclein, although the ability of cells to maintain a low cytosolic dopamine level after l-DOPA challenge was markedly inhibited by either protein. We also found that incubation with low-micromolar concentrations of WT, A30P, or A53T α-synuclein inhibited ATP-dependent maintenance of pH gradients in isolated chromaffin vesicles and that the WT protein was significantly less potent in inducing the proton leakage. In summary, we demonstrate that overexpression of different types of α-synuclein disrupts vesicular pH and leads to a marked increase in the levels of cytosolic catechol species, an effect that may in turn trigger cellular oxyradical damage. Although multiple molecular mechanisms may be responsible for the perturbation of cytosolic catecholamine homeostasis, this study provides critical evidence about how α-synuclein might exert its cytotoxicity and selectively damage catecholaminergic cells.

[1]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[2]  E. Pothos,et al.  l‐3,4‐Dihydroxyphenylalanine Increases the Quantal Size of Exocytotic Dopamine Release In Vitro , 1996, Journal of neurochemistry.

[3]  N. Hattori,et al.  A Combinatorial Code for the Interaction of α-Synuclein with Membranes* , 2005, Journal of Biological Chemistry.

[4]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[5]  J. Trojanowski,et al.  Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.

[6]  B. Shastry,et al.  Parkinson disease: etiology, pathogenesis and future of gene therapy , 2001, Neuroscience Research.

[7]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[8]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[9]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[10]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[11]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[12]  P. S. St George-Hyslop,et al.  Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein , 2002 .

[13]  P. Brundin,et al.  Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.

[14]  D. Sulzer,et al.  Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action , 1990, Neuron.

[15]  T. Hastings,et al.  Could a loss of alpha-synuclein function put dopaminergic neurons at risk? , 2004, Journal of neurochemistry.

[16]  N. Hattori,et al.  A combinatorial code for the interaction of alpha-synuclein with membranes. , 2005, The Journal of biological chemistry.

[17]  M. LaVoie,et al.  Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.

[18]  P. Lansbury,et al.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.

[19]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Vrana,et al.  Cytotoxic and genotoxic potential of dopamine , 1999, Journal of neuroscience research.

[22]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[23]  H. Bergman,et al.  Physiology of Parkinson's Disease , 2008 .

[24]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[25]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[26]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[27]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[28]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[29]  P. S. St George-Hyslop,et al.  Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. , 2002, Journal of molecular biology.

[30]  R. Wightman,et al.  Fast-scan voltammetry of biogenic amines. , 1988, Analytical chemistry.

[31]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[32]  E. Masliah,et al.  Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP 1 1 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 2004, Experimental Neurology.

[33]  A. Ewing,et al.  Estimation of Free Dopamine in the Cytoplasm of the Giant Dopamine Cell of Planorbis corneus by Voltammetry and Capillary Electrophoresis , 1990, Journal of neurochemistry.

[34]  D. Sulzer,et al.  Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis , 2002, The Journal of Neuroscience.

[35]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[36]  A. Sidhu,et al.  α‐Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease , 2004 .

[37]  D. Eisenberg,et al.  A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter , 1992, Cell.

[38]  G. Alvarez de Toledo,et al.  The exocytotic event in chromaffin cells revealed by patch amperometry , 1997, Nature.

[39]  D. Sulzer,et al.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  R. Johnson,et al.  Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. , 1988, Physiological reviews.

[41]  D. Sulzer,et al.  Intracellular Patch Electrochemistry: Regulation of Cytosolic Catecholamines in Chromaffin Cells , 2003, The Journal of Neuroscience.

[42]  K. O’Malley,et al.  The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation , 2000, The Journal of Biological Chemistry.

[43]  Jean-Christophe Rochet,et al.  Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. , 2004, Journal of molecular neuroscience : MN.

[44]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Vila,et al.  Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.

[46]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[47]  N. Nelson,et al.  Chromaffin granule proton pump. , 1988, Methods in enzymology.

[48]  T. Hastings,et al.  Could a loss of α‐synuclein function put dopaminergic neurons at risk? , 2004 .

[49]  A. Sidhu,et al.  alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. , 2004, FEBS letters.

[50]  L. Greene,et al.  Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  L. Petrucelli,et al.  Gene dosage and pathogenesis of Parkinson's disease. , 2005, Trends in molecular medicine.

[52]  B. Waldeck,et al.  ANALYSIS OF THE MG++-ATP DEPENDENT STORAGE MECHANISM IN THE AMINE GRANULES OF THE ADRENAL MEDULLA. , 1963, Acta physiologica Scandinavica. Supplementum.